Cenobamate is a new antiseizure medication (ASM) indicated for the treatment of focal onset (partial-onset) seizures in adults [1]. The summary of product characteristics for Europe specifies the use of cenobamate as adjunctive treatment for focal onset seizures in adults whose epilepsy has not been adequately controlled with at least two ASMS [2]. The efficacy and safety of cenobamate were demonstrated in two double-blind, randomized, placebo-controlled, phase 2 clinical studies (NCT01397968; NCT01866111) in patients with uncontrolled focal seizures who were taking one to three concomitant ASMs [3,4].
13
FEB
FEB
0